News >

FDA Grants Nivolumab/Ipilimumab Priority Review for RCC

Jason M. Broderick @jasoncology
Published: Thursday, Dec 14, 2017

Murdo Gordon, BMS executive vice president and chief commercial officer
Murdo Gordon
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x